Triomics Raises $22 Million in Series B Funding
Triomics, a New York City-based company focused on advancing every cancer decision, announced it has raised $22 million in a Series B funding round. The round was led by Battery Ventures, with participation from Lightspeed, Nexus Venture Partners, Oncology Ventures, Precision Health Informatics, and Y Combinator.
Company Background
Founded by Hrituraj Singh and Sarim Khan, Triomics is dedicated to improving the decision-making process in cancer treatment. The company leverages data and technology to provide insights that can enhance treatment outcomes for cancer patients.
Investment Details
The Series B funding round, completed on May 28, 2026, saw significant interest from both existing and new investors. Battery Ventures took the lead in this round, marking a strong vote of confidence in Triomics’ mission and technology. Other notable investors included Lightspeed, Nexus Venture Partners, Oncology Ventures, Precision Health Informatics, and Y Combinator.
Planned Use of Funds
While specific plans for the new funds were not detailed, it is likely that Triomics will use this capital to further develop its technology platform, expand its team, and enhance its capabilities in providing actionable insights for cancer treatment. These efforts are expected to bolster the company's position in the healthcare technology sector.
Looking Ahead
With this latest injection of capital, Triomics is well-positioned to continue its work in transforming cancer care. As the company grows, it will likely focus on expanding its reach and refining its technology to better serve healthcare providers and patients alike.